Reported about 6 hours ago
A recent proposed coverage decision by the Centers for Medicare and Medicaid Services (CMS) for renal denervation is set to significantly increase the patient pool for Medtronic, according to BTIG analyst Ryan Zimmerman. He maintains a neutral rating on Medtronic but acknowledges that this development is beneficial for the company, which has been preparing for this coverage with its Symplicity Spyral launch.
Source: YAHOO